Information Provided By: 
Fly News Breaks for May 16, 2016
DVA
May 16, 2016 | 07:22 EDT
Baird raised its price target on DaVita to $90 from $82 ahead of the company's Capital Markets Day. The firm believes the company's Kidney Care guidance is too low and should move higher as the year plays out. Baird reiterated its Outperform rating on DaVita shares, also citing its ESA therapy optionality, solid free cash flow, and valuation.
News For DVA From the Last 2 Days
There are no results for your query DVA
